Letter to the editor concerning the article: “Comparative safety and benefit-risk profile of biologics and oral treatments for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data” - 12/10/21
Doi : 10.1016/j.jaad.2021.05.068
Dan Pettitt, DVM, MSc, MBA a, ⁎ 
, Michael Plotnick, MD b, Lloyd S. Miller, MD, PhD c, Jesse A. Berlin, ScD d
, Michael Plotnick, MD b, Lloyd S. Miller, MD, PhD c, Jesse A. Berlin, ScD d a Immunology Global Market Access and Health Economics, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania
b Immunology Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, Pennsylvania
c Janssen Research & Development, Spring House, Pennsylvania
d Johnson & Johnson, Titusville, New Jersey
∗Correspondence to: Dan Pettitt, DVM, MSc, MBA, Vice President, Immunology Global Market Access and Health Economics, Janssen Pharmaceutical Companies of Johnson & Johnson, Horsham, PA 19004Vice PresidentImmunology Global Market Access and Health EconomicsJanssen Pharmaceutical Companies of Johnson & JohnsonHorshamPA19004
Le texte complet de cet article est disponible en PDF.
| Funding sources: The authors of this letter are all employees of Janssen Pharmaceutica, and Johnson & Johnson. |
|
| IRB approval status: Not applicable. |
© 2021
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 85 - N° 5
P. e305-e306 - novembre 2021 Retour au numéro
Article précédent
- Response to: Momen et al's “Discriminating minor and major forms of drug reaction with eosinophilia and systemic symptoms: Facial edema aligns to the severe phenotype”
- Hui Mei Cheng, Hong Liang Tey
- Reply to: “Mohs micrographic surgery for male genital tumors: Local recurrence rates and patient-reported outcomes”
- Emi Dika, Federico Venturi
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?